Caribou Biosciences to Present at Upcoming Investor Conferences
November 17, 2021 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results
November 09, 2021 16:05 ET
|
Caribou Biosciences, Inc.
On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and Dara...
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
November 08, 2021 09:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Present at Upcoming Investor Conferences
October 20, 2021 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
September 29, 2021 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has...
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
September 27, 2021 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
September 02, 2021 16:05 ET
|
Caribou Biosciences, Inc.
Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares ANTLER Phase 1...
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
September 02, 2021 16:05 ET
|
Caribou Biosciences, Inc.
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications ...
Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference
September 01, 2021 08:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
August 25, 2021 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has...